title: A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.
abstract: S-1 is an oral anticancer fluoropyrimidine agent designed to elevate anticancer activity with a decrease in gastrointestinal toxicity. We conducted a phase II study to evaluate the efficacy and safety of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve patients were treated with S-1 administered orally at 40 mg/m(2) twice a day for 21 consecutive days, and cisplatin (60 mg/m(2)) infused intravenously on day 8, repeated every 5 weeks. Of the 44 patients enrolled in the study, 40 were assessable for efficacy and safety. The median number of cycles administered was 3 (range 1-9 cycles). Among the 40 assessable patients, 7 partial responses were observed, with an overall response rate (RR) of 17.5% [95% confidence interval (CI), 5.2-29.8]. Patients with squamous cell carcinoma showed a significantly higher RR (55.5%) than those with adenocarcinoma (9.1%) or other types of NSCLC (0%). The median progression-free survival was 4.3 months (95% CI, 3.4-4.9), the median survival time was 17.9 months (95% CI, 15.0-20.8), and the 1- and 2-year survival rates were 63.3 and 27.3%, respectively. Major grade 3-4 hematologic toxicities were leukocytopenia (7.5%), neutropenia (5.0%), anemia (15.0%) and thrombocytopenia (2.5%). No grade 4 non-hematologic toxicity or treatment-related death occurred. These results suggest that combination chemotherapy with S-1 plus cisplatin is a promising therapeutic candidate for patients with advanced NSCLC, particularly squamous cell carcinoma.
authors.affiliation: Department of Medical Oncology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima 770-8503.
authors.forename: Hideki
authors.initials: H
authors.lastname: Tomimoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Hanibuchi
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Ogushi
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Okano
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Shinohara
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Doi
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Takeuchi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Masahiko
authors.initials: M
authors.lastname: Azuma
authors.forename: Hiroya
authors.initials: H
authors.lastname: Tada
authors.forename: Takanori
authors.initials: T
authors.lastname: Kanematsu
authors.forename: Soji
authors.initials: S
authors.lastname: Kakiuchi
authors.forename: Hisatsugu
authors.initials: H
authors.lastname: Goto
authors.forename: Seiji
authors.initials: S
authors.lastname: Yano
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Nishioka
authors.forename: Saburo
authors.initials: S
authors.lastname: Sone